ZymoGenetics to Abandon Cancer Research, Cut 160 Jobs
Seattle, Washington's ZymoGenetics will cut 161 employees and discontinue research on cancer treatments. The firm will continue to market its only approved product, the blood-clotting…
Recothrom Thrombin